Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

ease that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the effect of the completion of the Phase 2 clinical trial for Amigal for the treatment of Fabry disease, the plans for the Phase 3 clinical trial for Amigal, the Phase II clinical trials for Plicera(TM) for the treatment of Gaucher disease, and the effect of the completion of the Phase I clinical trials for AT2220 for the treatment of Pompe disease may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cauti
'/>"/>
SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... BOSTON , May 26, 2015  PureTech, a ... toughest health challenges in disruptive ways, announced today that ... Foundation and former CEO of Pearson, has been appointed ... Senior Independent Director and that current Board member ... appointed Board Chairman. Dr. Ben Shapiro , PureTech,s ...
(Date:5/22/2015)... May 22, 2015 According to ... (1D & 2D Gel Electrophoresis, Agarose & Polyacrylamide Gel, ... Informatics), by Application & by End User - Global ... is expected to reach around $1.98 Billion by 2020 ... 2015 to 2020. Browse 226 ma ...
(Date:5/21/2015)... Seventh Wave Laboratories, a consulting-based contract ... pharmaceutical products and medical devices, announced the purchase of ... 50,000 sq. ft. building more than three times the ... Facility renovations will begin immediately and the gradual transition ... in September. , “We are excited about this ...
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
Breaking Biology Technology:PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 2PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 3Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
... SuperGen, Inc.,(Nasdaq: SUPG ), a pharmaceutical ... cancer therapies, today announced the company,s plans,to present ... "Molecular,Targets and Cancer Therapeutics" on October 23 and ... and non-clinical advances,in the following compounds: MP-470, SGI-1776 ...
... ... CCR9 for Gastrointestinal Diseases, MOUNTAIN VIEW, Calif., Oct. ... a Phase I clinical trial of CCX025,the company,s fourth ... the chemokine receptor known as CCR9.,Structurally distinct from Traficet-EN(TM) ...
... SUNNYVALE, Calif., Oct. 15 Cepheid (Nasdaq:,CPHD) ... Administration (FDA) categorized,Cepheid,s Xpert(TM) MRSA/SA Skin and ... under the Clinical Laboratory Improvement Amendments,(CLIA). The ... of,Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus,aureus (SA), ...
Cached Biology Technology:SuperGen to Present Data at EORTC-NCI-AACR 2ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development 2ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development 3ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development 4Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized 'Moderate Complexity' by FDA 2Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized 'Moderate Complexity' by FDA 3Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized 'Moderate Complexity' by FDA 4
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
(Date:5/14/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has ... in Smart Mobile Devices " report to their ... a watershed year for fingerprint sensors in smartphones and ... gave fingerprint sensors a raison d,etre in the mobile ... a must-have feature in flagship smartphones. The ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... farming is the major factor responsible for the destruction ... Indonesia, Malaysia, Thailand, Myanmar, Bangladesh, India, and Sri Lanka, ... of Biogeography. Giri and other researchers used more ... mangrove forests of the region, to quantify the rates ...
... nitrogen fertilizer is believed to benefit the soil by ... scientists dispute this view based on analyses of soil ... before the current practice began. The research, also ... world, was conducted by U of I soil scientists ...
... built at Scripps Institution of Oceanography at UC San ... state of all world oceans simultaneously is approaching its ... network of sensor-bearing profiling floats measures ocean water temperature, ... The Argo Steering Committee, the international panel of scientists ...
Cached Biology News:Study reveals that nitrogen fertilizers deplete soil organic carbon 2Study reveals that nitrogen fertilizers deplete soil organic carbon 3Unprecedented global measurement network achieves full coverage of oceans 2Unprecedented global measurement network achieves full coverage of oceans 3
... multicolor analysis in a modern flow cytometer, ... that are differentially labeled with fluorescent probes. ... typically used for cell labeling are broader ... a flow cytometers filters. Thus, the fluorescence ...
... kit allows a rapid and efficient ... FLAG-tagged protein. The immunoprecipitation is performed ... a highly specific monoclonal antibody covalently ... of affinity resin allows an efficient ...
This modular laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Configurations are available with vertical or horizontal flow; options include a wo...
This modular benchtop laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Options include a work bench, ionizaing bar, and air velocity gauge....
Biology Products: